Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 13(7): e16495, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34430110

ABSTRACT

Ischemic stroke is a rare phenomenon in young adults. A complete workup for hypercoagulable and myeloproliferative disorders is a cornerstone of evaluation. Essential thrombocytosis is a chronic myeloproliferative disorder that primarily involves platelets. It may remain undiagnosed in patients and subsequently present in the form of ischemic stroke. The management of this disorder is complex and often involves cytoreduction therapies. The initiation of these drugs in such patients may lead to unnecessary adverse effects and complications. This case report is an attempt to highlight an underappreciated cause of stroke when assessing young individuals.

2.
J Thorac Imaging ; 21(1): 43-6, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16538156

ABSTRACT

We report 2 patients with breast cancer who were treated with surgery and adjuvant chemotherapy for stage IIa and stage I breast cancers. Follow-up CT scans showed an anterior mediastinal mass, raising concern for tumor recurrence. Thymectomy performed on the first patient, and close follow-up with radiographic studies on the second patient, revealed benign thymic enlargement. Thymic hyperplasia can occur after cytotoxic chemotherapy and may be due to rebound enlargement after initial atrophy caused by chemotherapy. Thymic hyperplasia after chemotherapy has been reported mostly in young age groups and is described in the literature to be associated with various types of cancers, including lymphomas, leukemias, testicular cancer, and sarcomas, and in the stem cell transplant setting. This is the first case series describing 2 patients with early stage breast cancer who, following adjuvant standard dose chemotherapy, developed thymic hyperplasia. Awareness of this unusual side effect in patients treated with chemotherapy may prevent unnecessary investigation and surgical intervention.


Subject(s)
Breast Neoplasms/drug therapy , Thymus Hyperplasia/chemically induced , Thymus Hyperplasia/diagnosis , Adult , Breast Neoplasms/complications , Breast Neoplasms/surgery , Chemotherapy, Adjuvant/adverse effects , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Middle Aged , Thymectomy/methods , Tomography, X-Ray Computed/methods
3.
Am J Hematol ; 79(4): 303-8, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16044442

ABSTRACT

May-Hegglin anomaly (MHA) is a rare type of autosomal dominant platelet disorder associated with mutations in the gene encoding nonmuscle myosin heavy chain 9 (MYH9). It is characterized by the presence of large platelets, leukocyte inclusions, and thrombocytopenia. The bleeding tendency is usually mild, but severe hemorrhages have been reported. This is the first reported case of a patient with MHA who underwent craniotomy for intractable seizure disorder of temporal lobe origin. Patients who have thrombocytopenia have a higher likelihood of developing intraoperative or postoperative intracranial hematoma and bleeding complications. The patient was administered desmopressin (DDAVP) prior to the neurosurgical procedure and had no complications. With this approach, the use of platelet concentrates could be avoided. We discuss the role of DDAVP in MHA and related platelet disorders and review the current literature.


Subject(s)
Blood Loss, Surgical/prevention & control , Craniotomy , Epilepsy/surgery , Perioperative Care/methods , Thrombocytopenia/surgery , Adult , Deamino Arginine Vasopressin/administration & dosage , Deamino Arginine Vasopressin/therapeutic use , Epilepsy/blood , Epilepsy/complications , Female , Hemostatics/administration & dosage , Hemostatics/therapeutic use , Humans , Pedigree , Platelet Count , Platelet Transfusion , Thrombocytopenia/blood , Thrombocytopenia/complications , Thrombocytopenia/genetics , Treatment Outcome
4.
Ann Pharmacother ; 38(2): 232-4, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14742756

ABSTRACT

OBJECTIVE: To report a case of rhabdomyolysis and acute renal failure associated with gemfibrozil monotherapy of hyperlipidemia. CASE SUMMARY: A 30-year-old white man with hypertension, type 1 diabetes mellitus, and hyperlipidemia was hospitalized due to myalgias, nausea, and vomiting that began after he started working as a jackhammer operator 4 days previously. His medications were lisinopril, aspirin, insulin, and gemfibrozil. Creatine kinase and creatinine, which previously had been mildly elevated and normal, respectively, were markedly elevated, consistent with rhabdomyolysis with acute renal failure. DISCUSSION: As of December 8, 2003, this is the only report of a patient with normal baseline creatinine level who developed rhabdomyolysis with acute renal failure associated with gemfibrozil monotherapy. Strenuous exertion, hypovolemia, and lisinopril use may have contributed to the severity of illness. An objective causality assessment revealed that an adverse drug reaction to gemfibrozil was possible. CONCLUSIONS: Gemfibrozil monotherapy of hyperlipidemia may predispose to rhabdomyolysis with acute renal failure. Patients using gemfibrozil should be cautioned regarding strenuous exertion, dehydration, and the need for prompt evaluation of myalgias.


Subject(s)
Acute Kidney Injury/chemically induced , Creatinine/blood , Gemfibrozil/adverse effects , Hyperlipidemias/drug therapy , Hypolipidemic Agents/adverse effects , Rhabdomyolysis/chemically induced , Adult , Diabetes Mellitus, Type 1/complications , Humans , Hyperlipidemias/complications , Hypertension/complications , Male , Physical Exertion , Rhabdomyolysis/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...